Glass House Brands (GLAS) Income from Non-Controlling Interests (2022 - 2026)
Glass House Brands (GLAS) posted quarterly Income from Non-Controlling Interests of $126000.0 for Q1 2026, down 73.42% quarter-over-quarter from $474000.0 in Q4 2025.
Glass House Brands (GLAS) Income from Non-Controlling Interests (2022 - 2026) Analysis & Trends
Glass House Brands (GLAS) has reported Income from Non-Controlling Interests for 5 consecutive years, with $126000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Non-Controlling Interests changed N/A year-over-year to $126000.0; the TTM figure through Mar 2026 stood at $781000.0 (changed N/A YoY), while the FY2025 annual figure was $707000.0, up 250.0% from the prior year.
- Income from Non-Controlling Interests fell to $126000.0 in Q1 2026 per GLAS's latest filing, from $474000.0 in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at $100.4 billion in Q2 2023 and bottomed at -$24.0 billion in Q2 2022.
- Historically, Income from Non-Controlling Interests has averaged $5.1 billion across 5 years, with a median of $62528.0 in 2023.
- Annual changes were most pronounced in 2023 — Income from Non-Controlling Interests soared 1327.61% — and 2024, when it plunged 211.95%.
- Glass House Brands' Income from Non-Controlling Interests stood at -$8071.0 in 2022, then jumped by 1327.61% to $99080.0 in 2023, then soared by 295.64% to $392000.0 in 2024, then rose by 20.92% to $474000.0 in 2025, then plunged by 73.42% to $126000.0 in 2026.
- Business Quant data shows GLAS's Income from Non-Controlling Interests at $126000.0 in Q1 2026, $474000.0 in Q4 2025, and $106000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.05 Bn | 43.08 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.39 Bn | 39.74 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.78 Bn | 22.99 Bn | 5.10 Bn | 376,434.15 |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.92 Bn | 11.39 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 9.99 Bn | - | - |
| 10 | Glass House Brands | 832.85 Mn | 814.29 Mn | 15.77 Mn | 130,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 126,000.00 |
| Dec 31, 2025 | 474,000.00 |
| Sep 30, 2025 | 106,000.00 |
| Jun 30, 2025 | 75,000.00 |
| Dec 31, 2024 | 392,000.00 |
| Sep 30, 2024 | -70,000.00 |
| Jun 30, 2024 | 43,000.00 |
| Dec 31, 2023 | 99,080.00 |
| Sep 30, 2023 | 62,528.00 |
| Jun 30, 2023 | 100.41 Bn |
| Mar 31, 2023 | -37,000.00 |
| Dec 31, 2022 | -8,071.00 |
| Sep 30, 2022 | -7,044.00 |
| Jun 30, 2022 | -23.96 Bn |
| Mar 31, 2022 | -22,596.00 |